Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Weight gain in children and adolescents during treatment with atypical antipsychotics|
|Authors: ||Bervoets, Liene|
|Issue Date: ||2011|
|Citation: ||Belgian Association for the Study of Obesity - Free Communications Meeting, UCL, February 5, 2011|
|Abstract: ||Atypical antipsychotics, amongst which risperidone, are increasingly prescribed to children and adolescents with neuropsychiatric disorders. Their use has been associated with various health risks associated with weight gain, including obesity, diabetes mellitus, and dislipidemia. We will report on 2 boys who developed severe overweight during treatment with risperidone. An 8.5 years old boy more than doubled his weight during 4 years of treatment with risperidone resulting in a BMI increase from 17.0 kg/m² (+ 0.6 SDS) to 29.6 kg/m² (+ 2.9 SDS) at the age of 12.4 yrs. A 12.3 years old boy, treated since the age of 9.1 years with risperidone, also doubled his weight during 3 years of treatment with an increase in BMI from 16.4 kg/m² (+ 0.1 SDS) to 26.0 kg/m² (+ 1.9 SDS). Based on these two cases, the mechanisms involved in the by atypical antipsychotics induced weight gain will be discussed. It is hypothesized that atypical antipsychotics interfere with the appetite regulating system by interrupting the pathways between peripheral signals from the fat tissue and the gastrointestinal tract, and the hypothalamic appetite controlling centres. Guidelines for monitoring clinical and metabolic parameters will be proposed and preventive and therapeutic possibilities will be discussed.|
|Type: ||Conference Material|
|Appears in Collections: ||Research publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.